Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

• Status: Not yet recruiting
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vanderbilt University Medical Center
• Collaborator: ACADIA Pharmaceuticals Inc.
• Treatments: Pimavanserin

Criteria

Inclusion Criteria:

• Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants

• Healthy arm - age and gender matched to patient arm

• Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.

• Study partner available for study visits

Exclusion Criteria:

• Prior stroke or other uncontrolled serious neurological or medical illness

• Contra-indication or inability to tolerate MRI scan

• Use of serotonergic medications in the last 6 weeks

• Incapable of providing independent consent.

• Pregnant or breastfeeding women

• psychosis due to a metabolic, toxic, or primary psychiatric disease

• Deemed unable to complete neurocognitive testing

• For PD Participants: current or prior use of pimavanserin

• Use of antipsychotics in the last 2 weeks